Literature DB >> 31092596

Implications of Bacteriophage- and Bacteriophage Component-Based Therapies for the Clinical Microbiology Laboratory.

Katherine M Caflisch1, Robin Patel2,3.   

Abstract

Treatment of bacterial infections is increasingly challenged by resistance to currently available antibacterial agents. Not only are such agents less likely to be active today than they were in the past, but their very use has selected for and continues to select for further resistance. Additional strategies for the management of bacterial illnesses must be identified. In this review, bacteriophage-based therapies are presented as one promising approach. In anticipation of their potential expansion into clinical medicine, clinical microbiologists may wish to acquaint themselves with bacteriophages and their antibacterial components and, specifically, with methods for testing them. Here, we reviewed the literature spanning January 2007 to March 2019 on bacteriophage and phage-encoded protein therapies of relevance to clinical microbiology.
Copyright © 2019 American Society for Microbiology.

Entities:  

Keywords:  bacteriophages

Year:  2019        PMID: 31092596      PMCID: PMC6663902          DOI: 10.1128/JCM.00229-19

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  57 in total

1.  Comparison of several methods for preserving bacteriophages.

Authors:  W A CLARK
Journal:  Appl Microbiol       Date:  1962-09

Review 2.  Bacterial peptidoglycan (murein) hydrolases.

Authors:  Waldemar Vollmer; Bernard Joris; Paulette Charlier; Simon Foster
Journal:  FEMS Microbiol Rev       Date:  2008-02-11       Impact factor: 16.408

Review 3.  Exploring the prokaryotic virosphere.

Authors:  André M Comeau; Graham F Hatfull; Henry M Krisch; Debbie Lindell; Nicholas H Mann; David Prangishvili
Journal:  Res Microbiol       Date:  2008-05-29       Impact factor: 3.992

4.  European regulatory conundrum of phage therapy.

Authors:  Gilbert Verbeken; Daniel De Vos; Mario Vaneechoutte; Maya Merabishvili; Martin Zizi; Jean-Paul Pirnay
Journal:  Future Microbiol       Date:  2007-10       Impact factor: 3.165

5.  Topical treatment of Pseudomonas aeruginosa otitis of dogs with a bacteriophage mixture: a before/after clinical trial.

Authors:  Catherine Hawkins; David Harper; David Burch; Erik Anggård; James Soothill
Journal:  Vet Microbiol       Date:  2010-05-12       Impact factor: 3.293

6.  Bacteriophage therapy of venous leg ulcers in humans: results of a phase I safety trial.

Authors:  D D Rhoads; R D Wolcott; M A Kuskowski; B M Wolcott; L S Ward; A Sulakvelidze
Journal:  J Wound Care       Date:  2009-06       Impact factor: 2.072

7.  Eradication of Enterococcus faecalis by phage therapy in chronic bacterial prostatitis--case report.

Authors:  S Letkiewicz; R Miedzybrodzki; W Fortuna; B Weber-Dabrowska; A Górski
Journal:  Folia Microbiol (Praha)       Date:  2009-11-24       Impact factor: 2.099

Review 8.  Novel alternatives to antibiotics: bacteriophages, bacterial cell wall hydrolases, and antimicrobial peptides.

Authors:  A Parisien; B Allain; J Zhang; R Mandeville; C Q Lan
Journal:  J Appl Microbiol       Date:  2008-01       Impact factor: 3.772

9.  A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy.

Authors:  A Wright; C H Hawkins; E E Anggård; D R Harper
Journal:  Clin Otolaryngol       Date:  2009-08       Impact factor: 2.597

10.  Quality-controlled small-scale production of a well-defined bacteriophage cocktail for use in human clinical trials.

Authors:  Maya Merabishvili; Jean-Paul Pirnay; Gilbert Verbeken; Nina Chanishvili; Marina Tediashvili; Nino Lashkhi; Thea Glonti; Victor Krylov; Jan Mast; Luc Van Parys; Rob Lavigne; Guido Volckaert; Wesley Mattheus; Gunther Verween; Peter De Corte; Thomas Rose; Serge Jennes; Martin Zizi; Daniel De Vos; Mario Vaneechoutte
Journal:  PLoS One       Date:  2009-03-20       Impact factor: 3.240

View more
  7 in total

Review 1.  Biological challenges of phage therapy and proposed solutions: a literature review.

Authors:  Katherine M Caflisch; Gina A Suh; Robin Patel
Journal:  Expert Rev Anti Infect Ther       Date:  2019-12-02       Impact factor: 5.091

Review 2.  Multidrug Resistant Acinetobacter baumannii: Resistance by Any Other Name Would Still be Hard to Treat.

Authors:  David A Butler; Mark Biagi; Xing Tan; Samah Qasmieh; Zackery P Bulman; Eric Wenzler
Journal:  Curr Infect Dis Rep       Date:  2019-11-16       Impact factor: 3.725

3.  Phage Activity against Planktonic and Biofilm Staphylococcus aureus Periprosthetic Joint Infection Isolates.

Authors:  Katherine M C Totten; Robin Patel
Journal:  Antimicrob Agents Chemother       Date:  2021-10-18       Impact factor: 5.938

4.  Bacteriophages as Adjuvant to Antibiotics for the Treatment of Periprosthetic Joint Infection Caused by Multidrug-Resistant Pseudomonas aeruginosa.

Authors:  Tamta Tkhilaishvili; Tobias Winkler; Michael Müller; Carsten Perka; Andrej Trampuz
Journal:  Antimicrob Agents Chemother       Date:  2019-12-20       Impact factor: 5.191

5.  Isolation and Characterization of a New Phage Infecting Elizabethkingia anophelis and Evaluation of Its Therapeutic Efficacy in vitro and in vivo.

Authors:  Shih-Yi Peng; Li-Kuang Chen; Wen-Jui Wu; Prajna Paramita; Po-Wei Yang; Yun-Zhong Li; Meng-Jiun Lai; Kai-Chih Chang
Journal:  Front Microbiol       Date:  2020-05-13       Impact factor: 5.640

Review 6.  Alternatives to Conventional Antibiotic Therapy: Potential Therapeutic Strategies of Combating Antimicrobial-Resistance and Biofilm-Related Infections.

Authors:  Qian Xu; Xuefeng Hu; Yunbing Wang
Journal:  Mol Biotechnol       Date:  2021-07-26       Impact factor: 2.695

Review 7.  Considerations for the Use of Phage Therapy in Clinical Practice.

Authors:  Gina A Suh; Thomas P Lodise; Pranita D Tamma; Jane M Knisely; Jose Alexander; Saima Aslam; Karen D Barton; Erica Bizzell; Katherine M C Totten; Joseph L Campbell; Benjamin K Chan; Scott A Cunningham; Katherine E Goodman; Kerryl E Greenwood-Quaintance; Anthony D Harris; Shayla Hesse; Anthony Maresso; Veronique Nussenblatt; David Pride; Michael J Rybak; Zoe Sund; David van Duin; Daria Van Tyne; Robin Patel
Journal:  Antimicrob Agents Chemother       Date:  2022-01-18       Impact factor: 5.191

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.